BeyondSpring, Inc. BYSI

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
40/100
Developing

Ranked against 712 peers in Biotechnology

About BeyondSpring, Inc.

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for … Full BYSI analysis →

Key strengths

  • ROIC Sustainably Above Peers ROIC at 88.3th percentile exceeds peers and WACC, demonstrating superior capital allocation.
  • Operating Leverage in Effect Operating leverage is evident (score 0.96), with margins expanding over time.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.08), raising refinancing risk.
  • Liquidity Concerns Liquidity is concerning (score 0.17), raising questions about short-term obligations.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
25
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where BYSI ranks in Biotechnology

BeyondSpring, Inc. ranks #367 of 713 scored companies in Biotechnology by moat score — the top 51%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
363 Upstream Bio, Inc. UPB 41/100 Developing
364 Coherus BioSciences, Inc. CHRS 41/100 Developing
365 ProMIS Neurosciences Inc. PMN 41/100 Developing
366 Shattuck Labs, Inc. STTK 40/100 Developing
367 BeyondSpring, Inc. BYSI 40/100 Developing
368 Oncternal Therapeutics, Inc. ONCT 40/100 Developing
369 Belite Bio, Inc BLTE 40/100 Developing
370 uniQure N.V. QURE 40/100 Developing
371 Viking Therapeutics, Inc. VKTX 40/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How BYSI scores on the Corporate Default defenses

Pricing Power

Score 25 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 28 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 27 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 72 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 15 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 76 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding BYSI's moat

What is BeyondSpring, Inc.'s moat score?

BeyondSpring, Inc. (BYSI) scores 40 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #367 of 713 scored companies in Biotechnology, the top 51%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Scale & Market Position (76/100) and its weakest is Resilience (15/100).

How does BeyondSpring, Inc. compare with other Biotechnology companies?

BeyondSpring, Inc. ranks #367 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Shattuck Labs, Inc. (STTK) at 40 just above it and Oncternal Therapeutics, Inc. (ONCT) at 40 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is BeyondSpring, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for BeyondSpring, Inc.?

The Corporate Default template measures 6 defenses, and BYSI scores: Pricing Power (25), Cost Advantage (28), Customer Stickiness (27), Capital Efficiency (72), Resilience (15), Scale & Market Position (76). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000